Nearly 49,000 courses of Eli Lilly’s bebtelovimab — a monoclonal antibody treatment effective against omicron — have been distributed throughout the U.S. since the FDA issued an emergency use authorization for the drug Feb. 11.
Read the full post on Becker's Hospital Review - Healthcare News
